MA56449A - Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine - Google Patents

Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Info

Publication number
MA56449A
MA56449A MA056449A MA56449A MA56449A MA 56449 A MA56449 A MA 56449A MA 056449 A MA056449 A MA 056449A MA 56449 A MA56449 A MA 56449A MA 56449 A MA56449 A MA 56449A
Authority
MA
Morocco
Prior art keywords
rilpivirine
methods
pediatric patients
treating hiv
hiv
Prior art date
Application number
MA056449A
Other languages
English (en)
Inventor
Herta Crauwels
Eygen Veerle Van
Simon Vanveggel
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56449A publication Critical patent/MA56449A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056449A 2019-07-03 2020-07-02 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine MA56449A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03

Publications (1)

Publication Number Publication Date
MA56449A true MA56449A (fr) 2022-05-11

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056449A MA56449A (fr) 2019-07-03 2020-07-02 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
MA056453A MA56453A (fr) 2019-07-03 2020-07-03 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA056453A MA56453A (fr) 2019-07-03 2020-07-03 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Country Status (14)

Country Link
US (3) US20210000823A1 (fr)
EP (2) EP3993799A1 (fr)
JP (4) JP2022538338A (fr)
KR (2) KR20220028049A (fr)
CN (2) CN114126655A (fr)
AU (2) AU2020300818A1 (fr)
BR (2) BR112021026916A2 (fr)
CA (1) CA3144307A1 (fr)
IL (1) IL289457A (fr)
JO (1) JOP20210347A1 (fr)
MA (2) MA56449A (fr)
MX (2) MX2022000060A (fr)
PH (1) PH12021553288A1 (fr)
WO (2) WO2021001508A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
NZ610729A (en) * 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
CA2921336A1 (fr) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
EP4233846B1 (fr) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Formulations pharmaceutiques
MA46563B1 (fr) * 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Also Published As

Publication number Publication date
WO2021001568A1 (fr) 2021-01-07
MX2021015627A (es) 2022-04-25
CN114126655A (zh) 2022-03-01
JP2026097814A (ja) 2026-06-16
BR112021026916A2 (pt) 2022-05-10
CN114080223A (zh) 2022-02-22
CA3144307A1 (fr) 2021-01-07
EP3993799A1 (fr) 2022-05-11
JP2022538449A (ja) 2022-09-02
JP2022538338A (ja) 2022-09-01
MX2022000060A (es) 2022-04-18
JP2026097815A (ja) 2026-06-16
KR20220028048A (ko) 2022-03-08
US20220313693A1 (en) 2022-10-06
CA3144534A1 (fr) 2021-01-07
KR20220028049A (ko) 2022-03-08
AU2020300818A1 (en) 2022-03-03
BR112021026739A2 (pt) 2022-04-26
EP3993800A1 (fr) 2022-05-11
US20240139186A1 (en) 2024-05-02
PH12021553288A1 (en) 2022-08-01
US20210000823A1 (en) 2021-01-07
WO2021001508A1 (fr) 2021-01-07
IL289457A (en) 2022-02-01
MA56453A (fr) 2022-05-11
JOP20210347A1 (ar) 2023-01-30
AU2020300033A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
FR24C1024I2 (fr) Combinaisons du dolutégravir et de la lamivudine destinées au traitement de l'infection au vih
WO2018115507A3 (fr) Vaccin contre l'hénipavirus
EP3302709A4 (fr) Méthodes et compositions pour le traitement guidé par arn de l'infection par le vih
EP3781214A4 (fr) Compositions et procédés de traitement de l'amyotrophie spinale
EP3397149A4 (fr) Cartographie et traitement de tissu
EP3313517A4 (fr) Systèmes et procédés de thérapie par histotripsie pour le traitement de tissu cérébral
EP3288957A4 (fr) Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
EP3445405A4 (fr) Oligomères antisens et procédés d'utilisation de ceux-ci pour le traitement de maladies associées au gène de l'alpha-glucosidase acide
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
EP2916827A4 (fr) Procédés et dispositifs pour le traitement de maladies oculaires chez des sujets humains
EP3592841A4 (fr) Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens
SI3830119T1 (sl) Protitelesa proti btn3a in njihova uporaba pri zdravljenju raka ali infekcijskih obolenj
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3347096A4 (fr) Traitement par inhalation d'oxyde nitrique pour nourrissons atteints de bronchiolite
EP3307913A4 (fr) Procédés de diagnostic et de traitement de l'autisme
EP3935078A4 (fr) Compositions et méthodes pour le diagnostic et le traitement de rétinopathies
EP2969004A4 (fr) Procédés de traitement d'infections chez des patients atteints de surpoids et d'obésité utilisant d'antibiotiques
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза
EP3341079A4 (fr) Procédés et compositions pour le diagnostic et le traitement du cancer
EP3962545A4 (fr) Compositions et procédés pour le traitement de la dégénérescence rétinienne
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
EP3810755A4 (fr) Compositions et méthodes de traitement du vih
EP3780952A4 (fr) Compositions et méthodes de traitement de la dystrophie musculaire de duchenne
MA56453A (fr) Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
MA56116A (fr) Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde